Scienture Holdings, Inc. (NASDAQ:SCNX) Short Interest Down 31.0% in October

Scienture Holdings, Inc. (NASDAQ:SCNX) saw a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 290,900 shares, a drop of 31.0% from the September 30th total of 421,400 shares. Based on an average daily trading volume, of 15,610,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.7% of the shares of the company are short sold. Approximately 1.7% of the shares of the company are short sold. Based on an average daily trading volume, of 15,610,000 shares, the days-to-cover ratio is presently 0.0 days.

Scienture Stock Performance

NASDAQ:SCNX traded down $0.07 during midday trading on Monday, reaching $0.71. 2,481,200 shares of the company traded hands, compared to its average volume of 6,034,343. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.11 and a quick ratio of 0.11. Scienture has a twelve month low of $0.46 and a twelve month high of $8.81. The company has a fifty day moving average price of $0.90 and a 200 day moving average price of $1.15. The firm has a market capitalization of $24.45 million, a price-to-earnings ratio of -0.26 and a beta of 3.11.

Scienture (NASDAQ:SCNX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.48) earnings per share for the quarter. Scienture had a negative net margin of 10,364.22% and a negative return on equity of 24.47%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Scienture in a research note on Wednesday, October 8th. Wall Street Zen cut Scienture from a “hold” rating to a “sell” rating in a research note on Sunday, August 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.